Garnet BioTherapeutics has developed a distinct population of "smart" bone-marrow derived cells capable of reducing inflammation and promoting healing. The firm also boasts a proprietary scalable cell expansion technology that can generate billions of patient doses of GBT009 from a single bone marrow donor, the company claims. The company plans to develop therapies to reduce scarring and accelerate healing in post-surgical wound repair and other dermatology applications. It may eventually expand into additional reconstructive and surgical procedures.
1 Great Valley Parkway
Suite 12
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
